Critical issues in mucosal immunity for HIV-1 vaccine development.

Published

Journal Article (Review)

Development of a safe and effective vaccine for HIV-1 infection is a critical global priority. However, the nature of host-virus interactions that lead to early immunosuppression and CD4 depletion, HIV-1 diversity, and the inability of the immune system to eliminate the latently infected CD4 pool of cells has to date thwarted successful vaccine development. Moreover, both the initial antibody-inducing vaccine (protein envelope gp120) and cell-mediated vaccine (recombinant adenovirus containing HIV-1 genes) strategies have failed in efficacy trials, and the latter cell-mediated vaccine appeared to have caused enhanced HIV-1 acquisition. Thus basic and translational research to understand why current vaccines have failed and elucidation of new mechanisms of virus control at mucosal surfaces is essential for eventual successful development of a preventive HIV-1 vaccine.

Full Text

Duke Authors

Cited Authors

  • Haynes, BF; Shattock, RJ

Published Date

  • July 2008

Published In

Volume / Issue

  • 122 / 1

Start / End Page

  • 3 - 9

PubMed ID

  • 18468671

Pubmed Central ID

  • 18468671

Electronic International Standard Serial Number (EISSN)

  • 1097-6825

Digital Object Identifier (DOI)

  • 10.1016/j.jaci.2008.03.036

Language

  • eng

Conference Location

  • United States